Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

Core Insights - Madrigal Pharmaceuticals, Inc. is focused on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with significant unmet medical needs [1] - The company's primary medication, Rezdiffra (resmetirom), is a once-daily oral THR-β agonist aimed at addressing the underlying causes of NASH [1] Financial and Operational Updates - Madrigal Pharmaceuticals will release its second-quarter 2024 financial results on August 7, 2024, before the U.S. financial markets open [5] - Following the announcement, a live webcast will be hosted by the company's management at 8 a.m. Eastern Time to review the financial and operating results [3][5] Webcast Information - The live webcast can be accessed through the Investor Relations section of the Madrigal Pharmaceuticals website, with a recommendation for participants to register at least 15 minutes prior to the scheduled time [6]